Alerta

COMPOSITIONS AND METHODS FOR IBD PATIENTS USING STOOL-DERIVED EUKARYOTIC NUCLEIC ACIDS

Absstract of: US20260234724A1

The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).

MICROBIAL AND HUMAN CELL-FREE DNA BIOMARKERS FOR DIAGNOSING AND ASSESSING THE SEVERITY OF INFLAMMATORY BOWEL DISEASE

Absstract of: AU2025213436A1

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.

POINT-OF-CARE TEST DIAGNOSTIC MARKERS AND ADJUVANT TREATMENTS FOR GASTROINTESTINAL DISEASES

Absstract of: WO2025075714A1

Described herein is a method of diagnosing and/or treating irritable bowel syndrome (IBS) in a subject. The method comprises determining a fatty acid profile in a stool sample of the subject; and comparing the fatty acid profile with a first reference profile indicating an absence of IBS or a second reference profile indicating IBS. Also described herein is a composition for treating IBS, which comprises two or more of a Monoglobaceae bacterium, a Lachnospiraceae bacterium; and a Ruminococcaceae bacterium, as well as a method of treating IBS using the same.

COMBINATION ASSAY OF CYTOKINES AND HUMAN ANTIBODIES TO MAP FOR THE DIAGNOSIS OF CROHN'S DISEASE, TUBERCULOSIS, AND OTHER BACTERIAL DISEASES

Absstract of: AU2025224860A1

A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.

PREDICTION OF CROHN'S DISEASE RECURRENCE

Absstract of: WO2026162782A1

The present invention relates to a method for the prediction of the risk of recurrence of Crohn's disease (CD) after intestinal resection and anastomosis in a human subject based on the measure of the expression level of GPX4.

METHOD FOR IDENTIFYING A MULTI-PARAMETER PHENOTYPE OF MICROBIOTA

Absstract of: US20260227396A1

0000 A method for identifying a multi-parameter phenotype of microbiota. The method includes (i) providing a sample including microbiota, (ii) labeling the microbiota with multiple labels, each of which binds a phenotypic parameter of the microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. Also described is a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.

METHODS OF IDENTIFYING RESPONDERS TO TREATMENT FOR INFLAMMATORY BOWEL DISEASE

Absstract of: WO2026161796A1

The present disclosure relates to the use of biomarkers, e.g., TNF-α, IL-17F, GM-CSF, and combinations thereof, to identify the responsiveness of IBD patients to treatment with an anti-IL23 antagonist (e.g., anti-IL23 antibodies). The levels of biomarkers are compared to the levels of the same biomarkers in an individual having a known responsiveness status. Information provided by the disclosed method may be used to determine whether an IBD patient should be treated with an IL-23 antagonist or a treatment that does not target IL-23. Such information may also be used to determine if treatment with a certain agent should be commenced, suspended, or modified. Also disclosed herein are methods of determining the level of a biomarker associated with responsiveness of an individual to treatment with an IL-23 antagonist.

Methods for Detecting Post-Infectious Irritable Bowel Syndrome

Absstract of: US20260219280A1

Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.

HOXA11AS LONG NON-CODING RNA IN INFLAMMATORY BOWEL DISEASE

Absstract of: US20260218299A1

0000 Provided herein are gene replacement approaches to restore HOXA11AS in the colon for patients with IBD, e.g., UC. Further, since HOXA11os levels inversely correlate with disease severity this lncRNA can also be used as a sensitive colon specific disease relevant biomarker.

IMMUNOASSAY FOR INFLAMMATORY BOWEL DISEASE

Absstract of: AU2025224738A1

The present invention relates to methods of immunoassay for detecting or monitoring inflammatory bowel disease or a severity thereof in a patient. In certain embodiments, the inflammatory bowel disease may be ulcerative colitis.

用于治疗腹泻型肠易激综合征的N-油酰乙醇胺和直肠真杆菌

Absstract of: WO2025185743A1

Use of N-oleoylethanolamide(OEA) or a microbiota OEA producer, such as Eubacterium rectale, in the preparation of medicament for the treatment of irritable bowel syndrome (IBS).

COMPOSITIONS, DEVICES, AND METHODS OF ULCERATIVE COLITIS SENSITIVITY TESTING

Absstract of: US20260210970A1

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.

METHOD FOR EXAMINING INFLAMMATORY BOWEL DISEASE AND METHOD FOR SCREENING THERAPEUTIC AGENT

Absstract of: WO2026155051A1

The present invention provides an examination method for identifying a biomarker capable of detecting the remission phase of an inflammatory bowel disease, and assisting in the diagnosis of the inflammatory bowel disease, the monitoring of disease progression, or the determination of therapeutic effect.　Focusing attention on myeloid immune cells that play an important role in the pathogenesis of inflammatory bowel disease, the present inventors considered that young myeloid immune cells potentially increase even in the remission phase and may induce transition to the active phase by progression of the disease. The present inventors then proceeded with intensive studies thereon. As a result, the present inventors found that CD11b, CD33, and CD84-positive (CD11b+CD33+CD84+) cells, which are precursor cells of myeloid immune cells, can serve as blood markers for inflammatory bowel disease. Further investigation revealed that Membrane-Spanning 4-Domains A3 (Ms4a3)-positive (Ms4a3+) cells, and Ms4a3 and CD84-positive (Ms4a3+CD84+) cells significantly increase not only in the active phase but also in the remission phase, and are significantly greater in number in the active phase than in the remission phase.

METHODS, KITS AND COMPOSITIONS FOR THE TREATMENT OF FOOD PROTEIN INDUCED ENTEROCOLITIS SYNDROME AND IRRITABLE BOWEL SYNDROME

Absstract of: US20260209366A1

This invention describes methods, kits, and compositions for treating Food Protein-Induced Enterocolitis Syndrome (FPIES) and a food-triggered endotype of IBS by modulating the IL-4/IL-13→IL-4Rα axis and/or the OX40-OX40L costimulatory pathway, with patient selection and monitoring guided by blood biomarkers (elevated OX40L on dendritic cells and/or OX40 on lymphocytes, including food antigen-stimulated assays). In case examples, IL-4Rα blockade (e.g., dupilumab) produced rapid, durable clinical remission with successful food reintroduction, accompanied by reduced dendritic-cell OX40L and modulation of circulating CRTH2+ Tc2 cells, whereas OX40L-low, non-food-trigger IBS showed no response—supporting a biomarker-defined responder population. Collectively, this invention demonstrates a precision framework in which IL-4Rα and OX40/OX40L antagonists—alone or in combination—enable diet liberalization and induce tolerance in FPIES and food-triggered IBS.

REVERSIBLE BACTERIAL PHSE-VARIATIONS AND USES THEREOF IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS

Absstract of: US20260209867A1

0000 The present disclosure relates to reversible phase variations in bacteria e.g., residing in a microbiome or any environment, and uses thereof in determining a physiological and/or environmental condition or state of a subject or a media and/or or habitat. The present disclosure thus provides methods and personalized therapeutic methods and kits.

ANTI-IL23 AND ANTI-TNFa ANTIBODIES: COMPOSITIONS AND VETERINARY USE

Absstract of: US20260209333A1

0000 Provided are various embodiments relating to caninized, felinized, or equinized antibodies that bind canine, feline, and/or equine IL23 and/or TNFα, including bispecific antibodies that bind to both IL23 and TNFα. Such antibodies can be used alone or in combination in methods to treat canine, feline, and/or equine subjects with inflammatory conditions, such as inflammatory conditions in canines and felines, such as inflammatory bowel disease (IBD), osteoarthritis, and gastroenteritis.

AUTOMATIZED DETECTION OF INTESTINAL INFLAMMATION IN CROHN'S DISEASE USING CONVOLUTIONAL NEURAL NETWORK

Absstract of: US20260212495A1

0000 The invention relates to system and methods for predicting and/or diagnosing of IBD from ultrasound images according to one or more of diagnostic signs.

METHOD TO PREDICT SENSITIVITY TO EMULSIFIER

Absstract of: WO2026150017A1

The present invention relates to a method to predict the sensitivity of a subject to emulsifiers. Here, the inventors explored the use of an in vitro microbiota system and metagenome-based bioinformatic modeling to predict CMC sensitivity of a given microbiota. They found that CMC sensitivity associated with a unique metagenomic signature, supporting the notion that emulsifier sensitivity could be predicted from metagenomic data. They next confirmed that microbiotas predicted to be CMC-sensitive conferred CMC sensitivity when transplanted into colitis-prone IL-10-/- germfree mice. This approach validated the ability of an ex vivo approaches to predict CMC-sensitivity, thereby advancing development of microbiota- based personalized nutrition strategies. Thus, the present invention relates to a method to predict the sensitivity of a subject to emulsifiers comprising determining in a sample obtained from the subject the relative abundance of the microbiota-derived DNA markers listed in the Table A.

CIRCULATING PERIPHERAL BLOOD MONOCYTES AS A PROGNOSTIC MARKER FOR COMPLICATED AND RESISTANT CROHN'S DISEASE

Absstract of: US20260201470A1

0000 Described herein are systems and methods for identifying gene clusters in patients that have Crohn's Disease (CD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

Absstract of: EP4775989A2

The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring RORγt⁺Th or RORγt⁺Treg cell levels and treating the subject accordingly.

MEASUREMENT OF HYDROGEN SULFIDE DURING BREATH TESTING

Absstract of: WO2018156937A1

Described herein are methods of detecting levels hydrogen sulfide (H2S) to diagnose H2S positive disease or conditions. Examples of H2S positive diseases and conditions include small intestinal bacterial overgrowth, diarrhea, fatigue, bowel urgency and abdominal pain. The H2S level can guide treatments for subjects who have high levels of H2S.

USEFUL COMPOUNDS FOR MODULATING INFLAMMATION

Absstract of: US20260193242A1

0000 The present disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R to R<3 >and X are defined herein; pharmaceutical compositions; dosage forms comprising the compounds or pharmaceutical compositions, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, or treating sepsis in a subject in need thereof, comprising administering the compounds, pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof. 0000

PHARMACEUTICAL COMPOSITION FOR TREATING ULCERATIVE COLITIS AND PREPARATION THEREOF

Absstract of: US20260191892A1

0000 The present invention provides a pharmaceutical composition including berberine, militarine, liquiritin, curcumin and atractylenolide III. The pharmaceutical composition is proven to be effective on ulcerative colitis modulating targets including MAOA, MAPK14, AHR, PTGS2, PLA2G1B, and ALOX5. The present invention further provides a method of preparing the pharmaceutical composition including optimization of extraction, determining the quality markers, and optimization of temperature. The present invention further provides a method of treating or alleviating ulcerative colitis.

METHODS AND MODELS FOR POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

Absstract of: US20260193710A1

Provided herein are methods, systems, compositions and kits for modeling post-operative recurrence (POR) or postoperative prophylaxis persistence (POPP) in Crohn's disease patients. The present disclosure provides clinical, serologic, and genetic factors predictive of POR in patients with Crohn's disease. Also provided are clinical, serologic, and genetic factors predictive of POPP in Crohn's disease patients. The clinical, serologic, and genetic factors of the present disclosure are useful for selecting for prognosing, diagnosing, treatment, treating, monitoring a treatment, or optimizing a treatment for a Crohn's disease patient.

Clinical prediction model of anal fistula occurrence probability of Crohn disease patient and design method

Nº publicación: CN122337675A 03/07/2026

Applicant:

NO 1 AFFILIATED HOSPITAL ANHUI UNIV OF TRADITIONAL CHINESE MEDICINE
\u5B89\u5FBD\u4E2D\u533B\u836F\u5927\u5B66\u7B2C\u4E00\u9644\u5C5E\u533B\u9662\uFF08\u5B89\u5FBD\u7701\u4E2D\u533B\u9662\uFF09

Absstract of: CN122337675A

The invention provides a clinical prediction model of anal fistula occurrence probability of a Crohn disease patient and a design method, and belongs to the technical field of clinical medicine. The risk prediction model comprises: an input module receiving patient parameter indexes composed of age during diagnosis, biological agent mode switching and Monte's performance typing during primary definite diagnosis; the processing module is connected with the input module and is used for calculating the evaluation and prediction probability of the anal fistula of the patient suffering from the Crohn disease according to the following formula on the basis of the age during diagnosis, the biological agent mode switching and the Monte performance typing data during primary definite diagnosis; the output module is connected with the processing module and outputs the anal fistula risk probability, obtained by the risk prediction model, of the patient suffering from the Rohn disease. And respectively verifying the prediction model in the training set and the verification set by adopting the area under the curve of the working characteristic curve of the subject and the calibration curve so as to judge the distinction degree and the calibration degree of the prediction model. The risk of anal fistula of a patient suffering from Crohn's disease can be accurately predicted before treatment.